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FEARING FEAR ITSELF:  
THE PROPOSED GENETIC INFORMATION 
NONDISCRIMINATION ACT OF 2005 AND 
PUBLIC FEARS ABOUT GENETIC 
INFORMATION 
Rivka Jungreis∗ 
“Men and women will increasingly be judged not by the 
color of their skin but by the content of their 
chromosomes.”1 
INTRODUCTION 
With the completion of the Human Genome Project in 2003, 
medicine and scientific research have embarked on a new era of 
possibility.2 Among the prospects to which we can look forward 
as a result of this development are improved disease diagnosis 
and assessment of disease susceptibility, vastly improved 
                                                          
 ∗ B.S. Interdisciplinary Sciences, Touro College, M.S. Biology, NYU 
Graduate School of Arts and Sciences, J.D. Candidate 2008, Brooklyn Law 
School. The author would like to thank Rabbi Jacob and Shifrah Jungreis for 
their boundless support and encouragement, Yisrael Jungreis and Miriam 
Jungreis for providing the most worthwhile of distractions during the writing 
process, and most of all Tzvi Hersh Jungreis for his constant devotion, love 
and support. Without all of your help, this would not have been possible. 
1 Andrew Sullivan, The Way We Live Now: 7-23-00: Counter Culture; 
Promotion of the Fittest, N.Y. TIMES, July 23, 2000, at F16 (proposing that 
in the wake of the Human Genome Project, genetic discrimination is both 
rational and inevitable). 
2 See The Future of Genomics: Hearing Before the Subcomm. on Health 
of the H. Comm. on Energy and Commerce, 108th Cong. (2003) (statement 
of Francis A. Collins, Director, National Human Genome Research Institute). 
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treatment and outcomes, and the progression of scientific 
research.3 Yet, along with the promise that genetic testing 
shows, new genetic technologies create additional possibilities 
for discrimination based on a person’s genetic makeup.4 
Pursuant to this concern, numerous propositions for federal 
legislative initiatives targeting genetic discrimination in health 
insurance and in the workplace have appeared in Congress over 
the last decade.5 
This Note argues that a federal statute addressing genetic 
discrimination in the workplace and in insurance underwriting is 
prudent. Although the fear of genetic discrimination remains 
more persistent than the discrimination itself, it is important to 
address that fear, as it deters many people from undergoing 
genetic testing.6 This Note also argues that educational initiatives 
alone cannot accomplish a reduction of the fear in a timely 
manner. 
Section I provides a brief overview of genetic information 
and the current state of genetic testing. Section II discusses the 
occurrence of genetic discrimination in employment and in 
health insurance, and Section III describes H.R. 1227, the 
Genetic Information Nondiscrimination Act of 2005 (GINA), 
which is the current version of proposed federal legislation 
targeting such discrimination.7 Section IV sets forth a 
comprehensive assessment of the desirability of passing such 
                                                          
3 See id. 
4 See Genetic Discrimination in Health Insurance, What is the issue?, 
http://www.genome.gov/10002328 (last visited Oct. 16, 2006). 
5 Genetic Discrimination in Health Insurance, What are the legislative 
protections?, http://www.genome.gov/10002328 (last visited Oct. 16, 2006) 
(“Nine bills were introduced in the 106th Congress (1999-2000), and four in 
the 107th Congress (2001-02).”). Five bills were introduced in the 108th 
Congress (2003-04). In the current Congress, a bill was unanimously passed 
in the Senate, and is pending in the House. See Federal Legislation about 
Genetic Privacy, http://www.genome.gov/11510239 (last visited Oct. 16, 
2005). 
6 See Brian C. Watts, V. Health Law: The Genetic Testing Privacy Act, 
2003 UTAH L. REV. 807, 809 (2003). 
7 H.R. 1227, 109th Cong. (2005). 
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legislation. The Note concludes that federal legislation is 
warranted, and that GINA provides a viable solution to the 
problems of genetic discrimination. 
 
I. BACKGROUND ON GENETIC INFORMATION; CURRENT 
DEVELOPMENTS 
Genetic information is contained in the DNA of every living 
organism.8 Each molecule of DNA, or deoxyribonucleic acid, is 
composed of two paired strands of nucleotides which are twisted 
together to form a double helical structure.9 Nucleotides contain 
one of four nitrogenous bases.10 Each nucleotide base pair is 
connected to the next, forming the chain of pairs that make up 
DNA.11 In human cells, DNA is organized into twenty-three 
matched pairs of chromosomes.12 The DNA codes for the 
production of specific proteins in the cell, thereby directing the 
cell’s function.13 The vast majority of DNA found in human 
cells is uniform among all human beings.14 However, variations 
in the ordering of base pairs in an individual’s DNA account for 
differences in the population.15 During replication of the cell’s 
DNA, mistakes in the arrangement of the nucleotide bases can 
occur, resulting in mutations of the genetic material.16 
The recently completed Human Genome Project17 has opened 
                                                          
8 DNA, Funk & Wagnalls New Encyclopedia (2005). 
9 Nicholas Wade, Watson and Crick, Both Aligned and Apart, 
Reinvented Biology, N.Y. TIMES, Feb. 25, 2003, at F3. 




14 Jonathan Weems, A Proposal for a Federal Genetic Privacy Act, 24 J. 
LEGAL MED. 109, 111 (2003). 
15 Genetics, Funk & Wagnalls New Encyclopedia (2005). 
16 Id. 
17 The Project was completed in 2003, and provides a blueprint of all of 
the genetic data contained in the human genome. All About the Human 
Genome Project, http://www.genome.gov/10001772 (last visited Sep. 26, 
2006). 
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up new avenues of discovery for scientists and physicians 
seeking to understand the underlying genetic bases of various 
diseases and pathological states.18 It is believed that almost every 
human illness has a genetic component.19 By comparing the 
known genetic sequence garnered from the Human Genome 
Project with the genetic sequence of an affected population, 
scientists can identify the segment of the genome that is 
implicated in a particular condition.20 The capability for such 
identifications has led to the development of genetic testing. The 
detection of the presence or absence of particular DNA 
fragments in an individual’s genome is invaluable for accurate 
diagnosis of disease and for determination of the propensity of a 
patient to develop various conditions.21 As scientists continue to 
unravel the genetic code, the significance of genetic testing will 
surely increase.22 
There are currently over 900 different genetic tests 
                                                          
18 See Stephanie L. Anderson, Genetic Privacy: A Challenge to Medico-
Legal Norms, Graeme Laurie, 25 J. LEGAL MED. 119, 119 (2004) (book 
review). 
19 Abigail L. Rose, Nikki Peters, Judy A. Shea & Katrina Armstrong, 
Attitudes and Misconceptions about Predictive Genetic Testing for Cancer 
Risk, 8 COMMUNITY GENETICS 145, 148 (2005). This notion may be what 
prompted James Watson, the co-discoverer of the structure of DNA, to 
declare, “In large measure, our fate is in our genes.” Leon Jaroff, The Gene 
Hunt Scientists, TIME, March 20, 1989, at 67. 
20 Jennifer Chorpening, Genetic Disability: A Modest Proposal To 
Modify the ADA to Protect Against Some Forms of Genetic Discrimination, 
82 N.C.L. REV. 1441, 1442 (2004). 
21 See, e.g., Weems, supra note 14. An individual’s DNA can be easily 
examined once a tissue sample is obtained. A variety of procedures have been 
developed to accomplish this. Id.; See also Jordan K. Garrison, Note, Courts 
Face the Exciting and the Inevitable: DNA in Civil Trials, 23 REV. LITIG. 
435, 438 (2004) (quoting French Nobel laureate Jean Dausset on the value of 
genetic testing, “medicine was, in its history, first of all curative, then 
preventative and finally predictive, whereas today the order is reversed: 
initially predictive, then preventative and finally, only in desperation, 
curative.”). 
22 See, e.g., Weems, supra note 14; Anita Silvers & Michael Ashley 
Stein, Human Rights and Genetic Discrimination: Protecting Genomics’ 
Promise for Public Health, 31 J. L. MED. & ETHICS 377, 377 (2003). 
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available.23 Some of these tests are diagnostic, while others 
identify susceptibility to specific diseases.24 It is critical to 
understand the significance of these tests, and perhaps more 
importantly, to understand their limitations. A genetic test “can 
tell if a mutation is present, but that finding does not guarantee 
that disease will develop.”25 For example, a genetic test 
revealing that a woman’s DNA contains the BRCA1 gene 
indicates that she has an 80% chance of developing breast 
cancer.26 However, it is entirely possible that she will never 
develop the disease.27 Equally important, a negative result of a 
BRCA1 test does not mean that a woman is risk-free.28 She still 
sustains many other risk factors (both genetic and 
environmental).29 Although the result of this particular genetic 
test does not conclusively predict whether a woman will or will 
not develop breast cancer, the test remains useful because it 
allows a high risk individual to take preventative steps to reduce 
the probability of occurrence of disease.30 
More controversial are tests which screen for diseases for 
which there are no known ways of avoiding or limiting the 
severity of the disease.31 In addition, most pathophysiological 
conditions are complex, many requiring an interaction between 
                                                          
23 See Human Genome Project Information: Gene Testing, 
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.sht
ml (last visited Oct. 28, 2005). 
24 Id. 
25 Lydia Schindler, Donna Kerrigan, Jeanne Kellen & Brian Hollen, 





29 Only five to ten percent of all breast cancer incidence is attributed to a 
genetic factor. See National Cancer Institute, Genetic Testing for BRCA1 and 
BRCA2: It’s Your Choice (2002), http://www.cancer.gov/cancertopics 
/factsheet/Risk/BRCA. 
30 See, e.g., Mendel E. Singer & Randall D. Cebul, BRCA1: To Test or 
Not to Test, That is the Question, 7 HEALTH MATRIX 163, 164 (1997). 
31 See Schindler et al., supra note 25, at http://nci.nih.gov/cancertopics/ 
understandingcancer/genetesting/Slide32. 
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two or more defective genes.32 For many conditions, such as 
heart disease and diabetes, genetic susceptibility must be 
understood within the context of other important factors such as 
environmental influences, nutrition, and lifestyle.33 
II. OCCURRENCE OF GENETIC DISCRIMINATION 
Along with enhanced understanding and treatment of human 
disease, the completion of the Human Genome Project along 
with the growing availability of genetic testing has resulted in 
increased concern about genetic discrimination.34 Genetic 
discrimination has been defined in various ways. In one widely 
cited study of genetic discrimination, the term was defined as 
“the denial of rights, privileges or opportunities on the basis of 
information obtained from genetically-based diagnostic and 
prognostic tests.”35 Others extend the term to include “such 
denials on the basis of assumptions stemming from family 
histories . . . as well as from ethnic group identification.”36 
                                                          
32 GRAEME LAURIE, GENETIC PRIVACY: A CHALLENGE TO MEDICO-
LEGAL NORMS 94 (2002). Diseases which are caused by a single defective 
gene, such as cystic fibrosis, muscular dystrophy, and retinitis pigmentosa are 
more predictable. Jordan K. Garrison, Note, Courts Face the Exciting and 
the Inevitable: DNA in Civil Trials, 23 REV. LITIG. 435, 438-439 (2004). 
33 Jacquelyn Ann K. Kegley, Confused Legal and Medical Policy: The 
Misconceptions of Genetic Screening, 19 MED. & L. 197, 200 (2000). This 
explains the statement of Dr. Craig Venter at an event celebrating the 
completion of the Human Genome Project, “Our physiology is based on 
complex and seemingly infinite interactions amongst all our genes and the 
environment, just as our civilization is based on the interactions amongst all 
of us.” Remarks by President Bill Clinton and British Prime Minister Tony 
Blair at Announcement on Human Genome Project, Fed. News Serv. (2000). 
34 Following the announcement in 2000 that a rough map of the human 
genome had been created, this concern was expressed by Dr. Francis Collins, 
Dr. Craig Venter, and President Bill Clinton. See Remarks by President Bill 
Clinton and British Prime Minister Tony Blair at Announcement on Human 
Genome Project, Fed. News Serv. (2000). 
35 Lawrence O. Gostin, Genetic Discrimination: The Use of Genetically 
Based Diagnostic and Prognostic Tests by Employers and Insurers, 17 AM. J. 
L. & MED. 109 (1991). 
36 See Janet L. Dolgin, Personhood, Discrimination, and the New 
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Concerns about the misuse of genetic information, whether the 
information is gleaned from a genetic test or from an 
individual’s family history, are valid. While the discrimination 
may occur in a variety of arenas, the two particular areas of 
concern which have emerged are the employment setting and 
health insurance.37 
Genetic testing prior to finalizing employment decisions has 
become increasingly commonplace.38 Information obtained in a 
genetic screen can be used to predict the likelihood of certain 
risks associated with the potential employee, such as the need 
for increased health care benefits and workers’ compensation 
claims.39 It might also be used to predict cost-related factors 
such as potential absenteeism or employee turnover.40 Employers 
may request genetic information prior to hiring an employee in 
order to ascertain various safety risks linked to the nature of the 
employment.41 Several recent surveys indicated that workplace 
genetic discrimination does occur with some frequency.42 
                                                          
Genetics, 66 BROOK. L. REV. 755, 771 (2001). 
37 Deborah Hellman, What Makes Genetic Discrimination Exceptional?, 
29 AM. J. L. & MED. 77, 83 (2003). Other areas in which genetic 
discrimination may occur include child custody disputes, adoption prospects, 
and abortion. Id. 
38 Brian M. Holt, Genetically Defective: The Judicial Interpretation of 
the Americans with Disabilities Act Fails to Protect Against Genetic 
Discrimination in the Workplace, 35 J. MARSHALL L. REV. 457, 460 (2002); 
See Silvers & Stein, supra note 22, at n.23. 
39 Holt, supra note 38, at 460-61. 
40 See Jeremy A. Colby, An Analysis of Genetic Discrimination 
Legislation Proposed by the 105th Congress, 24 AM. J. L. & MED. 443, 462 
(1998). 
41 Chorpening, supra note 20, at 1445. For example, a workplace 
chemical, such as benzene, has been shown to be more carcinogenic in 
individuals with a particular genetic susceptibility. Screening potential 
employees for this sensitivity could result in a safer work environment. See 
id. at n.32. 
42 A 1996 survey conducted by the Genetic Alliance found 13% of 
respondents had experienced various forms of employment discrimination 
based on their genetic makeup. Watts, supra note 6, at 809. In 1989, a 
Congressional study found at least 12 Fortune 500 companies that used 
genetic monitoring to screen their employees. Robert F. Rich & Julian 
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Further, these issues have reached the courtroom as well via 
employees who claimed they were discriminated against on the 
basis of their genetic information.43 
In many instances, an employee’s genetic predisposition to 
develop a disease will have no impact on job performance.44 
Indeed, in the employment setting, this information is typically 
not discovered until after an offer of employment has been 
extended, indicating that the employer has already made a 
factual determination that the applicant is qualified to perform 
the job.45 Since genetic tests indicate only a propensity to 
develop a disease or condition, the employee may never be 
affected by it at all. Therefore, it is important to safeguard job 
applicants from genetic discrimination. 
Similarly, insurance companies have a cost incentive to 
discriminate based on information obtained through genetic tests, 
as this information can be an indicator of probable risk.46 
Indeed, pricing of insurance has always reflected risk, and in 
this way, people who are at lower risk are able to avoid the cost 
                                                          
Ziegler, Genetic Discrimination in Health Insurance—Comprehensive Legal 
Solutions for a (Not so) Special Problem?, 2 IND. HEALTH L. REV. 5, 5 
(2005). For a detailed discussion of the current state of genetic testing in the 
workplace environment, see Paul Steven Miller, Is There a Pink Slip in My 
Genes? Genetic Discrimination in the Workplace, 3 J. HEALTH CARE L. & 
POL’Y 225, 232-37 (2000). 
43 E.g. Norman-Bloodsaw v. Lawrence Berkeley Laboratory, 135 F.3d 
1260 (9th Cir. 1998) (in which an employer required genetic testing of 
particular groups of individuals prior to employment); in another case, the 
E.E.O.C. brought suit against Burlington Northern Santa Fe Railroad for 
secretly testing its employees for a rare genetic condition. The case was 
settled for 2.2 million dollars. See National Human Genome Institute, Cases 
of Genetic Discrimination (2006), http://www.genome.gov/12513976. 
44 See Nancy Lee Jones & Alison M. Smith, Genetic Information: Legal 
Issues Relating to Discrimination and Privacy, CRS REP. FOR CONG. NO. 
RL30006, at 4-5 (2005). 
45 See Nicole Silvestri, Echazabal and the Threat to Self-Defense: The 
Most Recent Call for a Consistent, Interstate Genetic Nondiscrimination 
Policy, 7 U. PA. J. LAB. & EMP. L. 409, 421 (2005). 
46 David F. Partlett, Misuse of Genetic Information: The Common Law 
and Professionals’ Liability, 42 WASHBURN L.J. 489, 503 (2003). 
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of subsidizing the higher risk population.47 
The Genetic Alliance, a national advocacy group for 
individuals with genetic diseases, recently reported that it 
receives an average of two complaints per week about genetic 
discrimination.48 However, the frequency of such complaints has 
not translated into frequent lawsuits by the victims. The 
discrepancy may be due not only to the fact that genetic 
discrimination can be difficult to prove, but also to the lack of a 
comprehensive genetic discrimination statute under which to sue. 
The current mélange of state and federal laws addressing genetic 
discrimination is, for the most part, too weak to support 
potential claims.49 Some victims have indicated a hesitancy to 
sue over genetic discrimination for fear of bureaucratic barriers 
as well as further negative treatment resulting from publicity of 
their genetic data.50 
External pressures exist for both insurers and employers to 
avoid discriminating based on genetic factors.51 Some insurers 
may be cognizant of the limitations of genetic tests as predictors 
of disease, while others may want to avoid the possibility of 
potentially damaging discrimination lawsuits.52 Employers may 
also seek to avoid such suits.53 However, occurrences of genetic 
discrimination in both employment and insurance are expected to 
increase over time as genetic testing becomes more 
comprehensive and methods even more sophisticated.54 
                                                          
47 Id. at 503-04. 
48 See Steve Lohr, I.B.M. to Put Genetic Data of Workers Off Limits, 
N.Y. TIMES, Oct. 10, 2005, at C1. 
49 See discussion of state and federal legislation infra Part IV.B-C; See 
also Tresa Baldas, Legal Tension Grows over Genetic Tests; Privacy, 
Potential Discrimination are Major Concerns, NAT’L L.J., Oct. 31, 2005, at 
P1. 
50 See Peter Aldhous, Victims of Genetic Discrimination Speak Up, NEW 
SCIENTIST, Nov. 5, 2005, at 7. 
51 Partlett, supra note 46, at 518-19. 
52 Id. 
53 Id. at 519. 
54 See Ronald M. Green & A. Matthew Thomas, DNA: Five 
Distinguishing Features for Policy Analysis, 11 HARV. J.L. & TECH. 571 
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Moreover, refinement of gene testing methodology will lead to 
reduced testing costs, further broadening the appeal of such tests 
to employers and insurers.55 
 
III. PURPOSE & SCOPE OF GINA—THE GENETIC INFORMATION 
NONDISCRIMINATION ACT 
The Genetic Information Nondiscrimination Act56 (GINA) 
was unanimously approved in the U.S. Senate on February 17, 
2005.57 An identical companion bill was introduced in the House 
of Representatives in March 2005.58 In addition to prohibiting 
genetic discrimination by employers and insurers,59 GINA 
contains provisions safeguarding the privacy of genetic 
information.60 Despite the unanimous Senate approval as well as 
the support of President Bush61 and numerous interest groups 
such as the American Medical Association and the ACLU,62 the 
bill remains pending in the House.63 
GINA was introduced as a targeted effort to combat genetic 
                                                          
(1998); See also Rich & Ziegler, supra note 42, at 14. 
55 Rich & Ziegler, supra note 42, at 5. 
56 Genetic Information Nondiscrimination Act, S. 306, 109th Cong. 
(2005) (identical to H.R. 1227, 109th Cong.). 
57 See Bill Summary & Status for the 109th Congress, S. 306, 
http://www.thomas.gov/cgi-bin/bdquery/z?d109:SN00306:@@@R (last 
visited October 11, 2006). 
58 Genetic Information Nondiscrimination Act, H.R. 1227, 109th Cong. 
(2005). 
59 See id. 
60 Id. 
61 Helen Dewar, Senate Backs Safeguards for Genetic Data; Employers, 
Insurers Targeted, THE WASH. POST, Oct. 15, 2003, at A10; Statement of 
Administration Policy, S. 306 – Genetic Information Nondiscrimination Act of 
2005, reprinted in 151 CONG. REC. S. 1481 (daily ed. Feb. 16, 2005). 
62 Rich & Ziegler, supra note 42, at 5. 
63 The legislation remains pending at the time of this publication. See 
Bill Summary & Status for the 109th Congress, H.R. 1227, 
http://thomas.loc.gov/cgi-bin/bdquery/z?d109:h.r.01227 (last visited 
September 8, 2006). There are currently 232 cosponsors in the House. Id. 
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discrimination.64 Its supporters found existing federal and state 
laws inadequate to provide the necessary protections to 
individuals seeking genetic tests.65 GINA is designed to combat 
discrimination which is based solely on genetic information, that 
is, information obtained through a genetic test or indicated by 
the occurrence of a defect or disease in an individual’s family.66 
Further, the existence of a request by an individual or an 
individual’s family member for genetic testing is also protected 
genetic information.67 The Act restricts both insurers and 
employers from using genetic information to discriminate in 
several ways. 
Title I of GINA amends three existing federal laws in order 
to expressly prohibit insurers from restricting or denying 
enrollment in any health plan based on an individual’s genetic 
information.68 It also prevents insurers from setting an 
individual’s premiums based on such information, or using such 
information for any underwriting purposes.69 Insurers are also 
barred from requiring an individual to undergo a genetic test as 
a condition of insurability or of continuing coverage.70 GINA 
provides broad protection to group health plan members by 
forbidding the adjustment of premiums for an entire group based 
on the genetic information of one or more individuals within the 
group.71 
Under Title II, employers, employment agencies, and labor 
organizations may not make hiring or membership decisions or 
otherwise discriminate against an individual based on that 
                                                          
64 See Genetic Information Nondiscrimination Act, H.R. 1227, 109th 
Cong. § 2 (2005). 
65 Id.; See also discussion infra Part IV.B-C. 
66 H.R. 1227, 109th Cong. § 201 (2005). 
67 Id. 
68 H.R. 1227, 109th Cong. §§ 101–103 (2005). The following federal 
laws are amended by GINA: The Employee Retirement Income Security Act 
of 1974, The Public Health Service Act, and Title XVIII of the Social 
Security Act. Id. 
69 H.R. 1227, 109th Cong. §§ 101(b), 104(b)(2) (2005). 
70 H.R. 1227, 109th Cong. § 101(b) (2005). 
71 Id. at § 101(a)(2)-(3). 
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person’s genetic information.72 For the most part, these entities 
may not “request, require, or purchase genetic information” 
about their employees, although there are five categories of 
exception.73 If an employer obtains genetic information through 
an exception, the employer may only disclose the information to 
specific parties as mandated by the particular exception.74 
Finally, Title II provides remedies to various groups of 
employees who have been the victim of an employment practice 
contrary to the provisions of the Act.75 The remedies include 
damages as well as costs and fees.76 
In accordance with the still evolving science of genetic 
testing and the uncertainties inherent in legislating a matter not 
yet fully developed, the drafters of GINA included a provision 
in the Act which provides for a review of the legislation six 
years after its enactment.77 Specifically, the bill provides for the 
establishment of a Genetic Nondiscrimination Study Commission 
six years after GINA is passed, to study the impact of the 
legislation, to report on the current status of genetic science, and 
to make recommendations to Congress accordingly.78 
The Genetic Information Nondiscrimination Act of 2005 
differs from previously proposed genetic nondiscrimination 
                                                          
72 Id. at §§ 202(a), 203(a), 204(a) (2005). 
73 Id. at §§ 202(b), 203(b), 204(b) (2005). The exceptions include, inter 
alia, where health or genetic services are offered by the employer as part of 
a wellness program, where the employee provides written authorization, 
where necessary for an employer to comply with the provisions of the Family 
and Medical Leave Act of 1993 (29 U.S.C. 2613), and where the genetic 
information is to be used for monitoring of the effects of toxic substances in 
compliance with a Federal genetic monitoring regulation such as the 
Occupational Safety and Health Act of 1977 (30 U.S.C. 801). Id. 
74 H.R. 1227, 109th Cong. § 206(b) (2005). For example, if the 
information was collected in order for the employer to comply with the 
provisions of the Family and Medical Leave Act, the information may be 
disclosed in connection with the employer’s compliance with the Act’s 
requirements. Id. 
75 H.R. 1227, 109th Cong. § 207 (2005). 
76 Id. 
77 Id. at § 208(b). 
78 Id. 
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legislation in several ways. Its definition of “genetic 
information” is more narrow, so that it excludes information 
about a genetic disease that is evident through a manifested 
disease or condition, as well as information obtained through a 
genetic test when the information is related to a manifested 
disease or condition.79 Other distinctions include the requirement 
that individuals with discrimination claims seek redress with the 
Equal Employment Opportunity Commission (EEOC) before 
filing claims for damages in court, and the adoption of standards 
for the amount of punitive damage awards that can be 
obtained.80 With these modifications, the current bill may be 
able to address some of the concerns that have prevented 
legislation from moving forward in previous sessions of 
Congress. 
IV. WHY FEDERAL GENETIC NONDISCRIMINATION LEGISLATION 
MUST BE PASSED 
Although GINA has generally achieved widespread backing 
and acceptance,81 some key groups remain unconvinced of the 
need for federal genetic nondiscrimination legislation.82 The 
bill’s opponents, most notably the U.S. Chamber of Commerce, 
cite several basic reasons for their reluctance to support the bill. 
As a threshold matter, they do not find genetic discrimination 
different from other types of health status discrimination.83 
                                                          
79 Id. at § 201 (2005). 
80  H.R. 1227, 109th Cong. § 207 (2005). 
81 See discussion supra Part III. In the House of Representatives, H.R. 
1227 has 232 cosponsors. See Bill Summary & Status for the 109th 
Congress, H.R. 1227, http://thomas.loc.gov/cgi-bin/bdquery/z?d109: 
h.r.01227 (last visited September 8, 2006). 
82 The two major groups opposing the legislation are the U.S. Chamber 
of Commerce and the National Association of Manufacturers. Frequently 
Asked Questions: Genetic Information Nondiscrimination Act (H.R. 1227), 
http://geneticfairness.org/faq.html (last visited November 25, 2005). 
83 See Hearing Before the H. Subcomm. on Employer-Employee 
Relations of the H. Comm. on Education and the Workforce, 108th Congress 
(2004) (statement of Lawrence Z. Lorber, Partner, Proskauer Rose LLP, on 
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Further, they maintain that recently enacted state genetic 
discrimination laws, as well as existing federal antidiscrimination 
laws, provide sufficient protections against genetic 
discrimination.84 Some believe that genetic discrimination rarely 
occurs, and that non-legislative means can be employed to 
vanquish such fears.85 This section addresses each of these 
claims and concludes that the need for a statute such as GINA is 
significant. 
A. Genetic Discrimination is Different from Other Types of 
Discrimination 
1.  Genetic Information is Different than  
Ordinary Medical Information 
Commentators caution against singling out parts of the 
population for inclusion in an antidiscrimination statute because 
of the likelihood that every person possesses genetic defects to 
some extent.86 Arguably, it is difficult to differentiate between 
discrimination based on genetic information and discrimination 
based on other medical or circumstantial information, 
particularly for multifactorial diseases.87 Genetic exceptionalism, 
the idea that a person who has a genetic predisposition to a 
disease should receive extra protection, but a person with an 
environmentally based disease should not, has been cited as an 
argument against legislation such as GINA.88 One concern of 
those who warn against genetic exceptionalism is that legislating 
                                                          
behalf of the United States Chamber of Commerce). 
84 See id. 
85 See id.; Mark A. Hall & Stephen S. Rich, Genetic Privacy Laws and 
Patients’ Fear of Discrimination by Health Insurers: The View from Genetic 
Counselors, 28 J. L. MED. & ETHICS 245, 254-55 (2000). 
86 See Chorpening, supra note 20, at 1472; Susan. M. Wolf, Beyond 
Genetic Discrimination: Toward the Broader Harm of Geneticism, 23 (4) J.L. 
MED. & ETHICS 345 (1995). 
87 See Silvers & Stein, supra note 22, at 382. 
88 See Chorpening, supra note 20, at 1472. 
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against genetic discrimination, in and of itself may effectively 
label those who are discriminated against as inferior to the 
purportedly “normal” population.89 
Despite these arguments, genetic discrimination is separate 
and distinct from other sorts of discrimination. While it has been 
suggested that genetic information should not be singled out for 
protection beyond other health related information,90 genetic 
information differs significantly. More than just another variety 
of medical examination, genetic testing “offer[s] tremendous 
quantitative differences.”91 Part of the difference is that genetic 
tests have the potential to reveal much more about a patient than 
any single medical test could. Testing for many genetic factors 
in a single profile is expected to become more cost effective, 
encouraging or even mandating testing for many factors even 
when information is only sought regarding one gene.92 A single 
genetic profile could include thousands of genetic risk factors for 
ailments ranging from diseases to psychosocial ailments, such as 
drug addiction or impulsiveness.93 In this way, genetic testing 
carries long range prediction capabilities apart from those of 
more traditional medical tests.94 
Another distinguishing factor between genetic information 
and other medical information is the way in which such data 
might be used by insurers for underwriting purposes. Arguably, 
GINA’s restrictions on the use of genetic information adversely 
                                                          
89 See Wolf, supra note 86. For a critique of Professor Wolf’s view of 
genetic exceptionalism, arguing that Wolf fails to explain why this sort of 
inequality is morally problematic, see Deborah Hellman, What Makes Genetic 
Discrimination Exceptional?, 29 AM. J. L. & MED. 77, 90-92 (2003). 
90 See, e.g., Chorpening, supra note 20, at 1441; Garrison, supra note 
21, at 446 (discussing the finding of the Task Force on Genetic Information 
and Insurance of the NIH-DOE Joint Working Group on the Ethical, Legal, 
and Social Implications of the Human Genome Project, denying genetic 
exceptionalism). 
91 Weems, supra note 14, at 111-12. 
92 See Michele Schoonmaker & Erin D. Williams, Genetic Testing: 
Scientific Background and Nondiscrimination Legislation, CRS REP. FOR 
CONG. NO. RL32478, at 17 (2005). 
93 Weems, supra note 14, at 111. 
94 See Schoonmaker & Williams, supra note 92, at 16. 
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affect the underwriting process, resulting in poorly leveraged 
premiums among individuals with varying degrees of risk.95 
However, due to the inconclusive nature of most test results 
(given that the majority of genetic diseases are multifactorial), it 
is unclear that such calculations would be reasonable. 
It is important to note that GINA does not address the use of 
medical information derived from methods other than genetic 
testing. Insurers may continue to use disease diagnosis 
(including diagnosis of a genetic disease) or other indicators of 
risk for underwriting purposes. The Act thus recognizes that it is 
the discriminatory use of inconclusive genetic information which 
requires protection, rather than a more appropriate use of 
existing disease for underwriting purposes. This is one of the 
ways in which H.R.1227 differs from previous incarnations of 
the bill, as its definition of “genetic information” excludes 
information obtained through a genetic test that is related to a 
clinically present disease.96 
2. Widespread Fear of Genetic Discrimination 
Prevents People from Getting Tested 
Perhaps the largest distinction between genetic and other 
forms of discrimination lies in the public perception of genetic 
testing.97 Despite the relatively low incidence of genetic 
discrimination, it is clear that many people forego possibly 
beneficial genetic testing for fear that discrimination may 
occur.98 For similar reasons, many decline participation in 
potentially valuable research trials.99 These fears exist in the 
absence of factual cases indicating that genetic discrimination 
                                                          
95 Rich & Ziegler, supra note 42, at 40. 
96 See H.R. 1227, 109th Cong. § 201 (2005). 
97 See Anderson, supra note 18, at 124. 
98 Hall & Rich, supra note 85, at 245; See also Watts, supra note 6, at 
809; Silvers & Stein, supra note 22, at 377. 
99 See Letter from The Secretary’s Advisory Committee on Genetic 
Testing to Secretary Tommy Thompson 1 (2001), http://www4.od.nih.gov/ 
oba/sacgt/ltr_to_secDHHS5-3-01.pdf. 
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actually occurs to any significant extent.100 Thus, even in the 
absence of the clear distinctions between genetic discrimination 
and other health-related discrimination described above, a 
practical need to address the fears arises. 
It is imperative to understand the bases for this fear in any 
effort to combat their existence. For some, the fear may be 
explained by examining the historical perceptions of those who 
were thought to be genetically inferior.101 However, the majority 
of the fear may be attributed to scientific illiteracy in the general 
public,102 misconceptions among various groups of people,103 
and the existence of other sorts of privacy invasions which leave 
individuals apprehensive about how their genetic privacy will be 
protected. 
There have been some historical incidents of discrimination 
on a genetic basis. In the early twentieth century the eugenics 
movement represented an attempt to weed out inferior people 
from the evolutionary chain.104 The movement was spurred by 
Charles Darwin’s work on evolution, and eugenics was thought 
to be the responsible way for society to promote the survival of 
the most suitable candidates to perpetuate the human species.105 
During the same time period, eugenics was also espoused by the 
Supreme Court, when it upheld a Virginia statute permitting the 
forced sterilization of a “feeble minded” woman, whose mother 
and child were also “feeble minded.”106 Writing for the 
                                                          
100 Hall & Rich, supra note 85, at 245. 
101 See, e.g., Rose et al., supra note 19, at 149. 
102 See Cornelia Dean, Scientific Savvy? In U.S., Not Much, N.Y. 
TIMES, Aug. 30, 2005, at F3. 
103 Hall & Rich, supra note 85, at 245 (blaming misconceptions for 
reluctance to undergo genetic testing); See also Kegley, supra note 33, at 198 
(discussing various misconceptions about genetic testing among individuals); 
Rose et al., supra note 19, at 148; Garrison, supra note 21, at 436 
(indicating that even courts are not immune from misconceptions regarding 
genetic information). 
104 Eugenics, Funk & Wagnalls New Encyclopedia (2004). 
105 Id. 
106 Buck v. Bell, 274 U.S. 200, 205 (1927). Many states enacted 
sterilization laws targeting genetically defective populations, following early 
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majority, Justice Holmes determined that it was prudent to 
prevent the birth of children likely to drain the resources of 
society, reasoning that, “It is better for all the world, if instead 
of waiting to execute degenerate offspring for crime, or to let 
them starve for their imbecility, society can prevent those who 
are manifestly unfit from continuing their kind.”107 The 
popularity of eugenics waned quickly during the Nazi era, when 
Hitler utilized eugenic philosophy to justify his schematic 
attempt to rid the world of allegedly inferior people, such as 
Jews and homosexuals.108 Although eugenics as a discipline is 
not currently favored by the scientific community, and no longer 
appeals to the general public, some fear lingers concerning a 
revival of this sort of discriminatory practice.109 
A more recent instance of genetic discrimination occurred in 
the 1970s with the discovery of a gene associated with sickle 
cell anemia.110 The gene is found primarily in African-American 
populations.111 Scientists found that carriers of the gene might be 
more susceptible to particular workplace toxins.112 As a result, 
many African Americans reported experiencing discrimination in 
                                                          
developments in genetic science at the beginning of the twentieth century. 
The targeted defects included mental illness, blindness, and hearing loss, 
among others. GINA is an effort to prevent such discriminatory practices in 
the wake of the current major expansion of the capabilities of genetic science. 
See Genetic Information Nondiscrimination Act, H.R. 1227, 109th Cong. § 2 
(2005). 
107 Id. at 207. 
108 See Weems, supra note 14, at 113. 
109 Id. See also Rose, supra note 19, at 148 (discussing a 2005 study in 
which some participants thought that the purpose of genetic testing was “to 
create a superior race”); Mark A. Rothstein, Preventing the Discovery of 
Plaintiff Genetic Profiles by Defendants Seeking to Limit Damages in 
Personal Injury Litigation, 71 IND. L. J. 877, 894 (1996) (discussing the 
possibility that genetic information may be used in the future for eugenic 
purposes). 
110 See, e.g., Marisa Anne Pagnattaro, Genetic Discrimination and the 
Workplace: Employee’s Right to Privacy v. Employer’s Need to Know, 39 
AM. BUS. L. J. 139, 146-47 (2001). 
111 Id. 
112 Id. 
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hiring and firing decisions.113 Some wrongly assumed that 
African Americans were more prone to genetic disease than 
other populations.114 It is possible that the fears underlying the 
reluctance of people to undergo genetic testing today may be 
understood in relation to this relatively recent occurrence of 
resultant discrimination. 
In addition to these historical incidents of genetic 
discrimination, the fear of genetic discrimination among the 
general public may be attributed in part to scientific illiteracy. 
One genetic counselor at a cancer clinic explained that patients 
who come in to clinics are very much aware, and afraid of 
genetic discrimination.115 Yet for the most part, they “don’t 
know anything about genetics,” nor can they identify what a 
geneticist or a genetics counselor is.116 Jon Miller, who studies 
the current level of scientific understanding among Americans, 
found in a recent survey that less than one-third of adults in this 
country could articulate what DNA is.117 In a recent interview, 
Miller said that less than 25% of Americans “are scientifically 
savvy and alert,” while the remainder of the population 
“[doesn’t] have a clue.”118 Perhaps more worrisome is the alarm 
expressed by some that scientific literacy among biomedical 
policy leaders may be low as well.119 
In a 1995 U.S. study, only about half of respondents 
                                                          
113 Id. 
114 This incorrect assumption has been made regarding other groups, 
particularly Ashkenazi Jews. See Janet L. Dolgin, Personhood, 
Discrimination, and the New Genetics, 66 BROOK. L. REV. 755, 790 (2001). 
In fact, everyone shares a similar risk of genetic mutations, as indicated by 
the statement of Dr. Francis Collins, “There is no evidence that the burden 
of genetic flaws is greater for one population than another.” Id. at 791. 
115 Hall & Rich, supra note 85, at 246. 
116 Id. 
117 Dean, supra note 102. Miller is the director of the Center for 
Biomedical Communications at Northwestern University Medical School, and 
is widely regarded as an authority on scientific literacy. Id. 
118 Id. 
119 JON D. MILLER & LINDA G. KIMMEL, BIOMEDICAL COMMUNICATIONS 
302 (2001); See also Rich & Ziegler, supra note 42, at 8. 
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understood that if a doctor tells a couple that a genetic test 
indicates that they have a one-in-four chance of having a child 
with a genetic disease, each child that the couple has would 
sustain the same risk of having the disease.120 Considering that 
about half of the populations in industrialized societies are active 
in deciding issues of public policy,121 and far less than half are 
considered “scientifically savvy,”122 it becomes clear that 
decision-making on many levels may be affected by fears that 
are not factually based. 
Given that so many in the general population lack basic 
scientific understanding, it is not surprising that misconceptions 
about genetic testing abound. One common misconception is the 
belief that genes alone determine disease states.123 With the 
exception of a few rare instances, most genes should actually be 
regarded as factors in a complex interaction of environmental 
elements which could potentially, but not determinedly, combine 
to bring about clinical disease.124 In some cases, fear of genetic 
discrimination is tied to the belief that a defective gene is 
somehow indicative of a defective identity.125 Under that 
perception, people are afraid that if a mutation or defect is 
discovered in their genetic makeup, they will be seen as inferior 
                                                          
120 JON D. MILLER, RAFAEL PARDO, & FUJIO NIWA, PUBLIC 
PERCEPTIONS OF SCIENCE AND TECHNOLOGY 54(1997). Respondents were 
asked to choose between four possible interpretations of the meaning of “one-
in-four chances.” The choices were: 
[a] if they have only three children, none will have the illness 
[b] if their first child has the illness, the next three will not 
[c] each of the couple’s children has the same risk of suffering from 
the illness 
[d] if their first three children are healthy, the fourth will have the 
illness. 
Id. 54% of respondents selected choice c. Id. 
121 Id. at 7. 
122 Dean, supra note 102. 
123 See Rose et al., supra note 19, at 148. 
124 Kegley, supra note 33, at 200. 
125 Id. at 199. 
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to others, and discrimination will result.126 These sorts of 
pervasive misconceptions among the general population are often 
determinative of whether someone will choose a genetic test.127 
Indeed, even when patients are informed that there have not 
been widespread reports of genetic discrimination, many still 
choose to forego testing.128 
Misconceptions concerning genetic information occur among 
insurers as well. For example, some genetics counselors warn 
patients who are considering genetic tests about the possibility of 
resultant insurance discrimination because they believe that 
insurers are likely to misconstrue the results of tests.129 An 
insurer may misinterpret a carrier as an affected person or a 
person at risk for the disease, or may not appreciate that 
although a genetic predisposition is present, symptoms may not 
manifest themselves for years.130 Thus, it is thought that there is 
a lack of scientifically sound judgment on the insurer level as 
well.131 As a result, even when an individual understands the 
limits and capabilities of genetic testing, that individual may still 
resist testing for fear that other parties may misconstrue the 
meaning of the test results. 
Another contributing factor to the fear of genetic 
discrimination is the vulnerability that people may feel as a 
result of other unrelated privacy intrusions. For example, 
identity theft is a common occurrence that receives widespread 
                                                          
126 Id. The fears include fears of societal discrimination, fueled by 
general societal misunderstanding of genetic defects. See Ronald M. Green & 
A. Matthew Thomas, DNA: Five Distinguishing Features for Policy Analysis, 
11 HARV. J.L. & TECH. 571, 584-85 (1998). This is particularly the case in 
the wake of recent claims by scientists of links between genetic mutations and 
behavioral traits. See Dolgin, supra note 36, at 767-68. 
127 Hall & Rich, supra note 85, at 245; see also Rose et al., supra note 
19, at 145. 
128 Hall & Rich, supra note 85, at 245. 
129 Id. at 247. 
130 Id. For example, insurers “may not appreciate the fact that mild 
forms of muscular dystrophy exist in which symptoms do not occur for many 
years.” Id. 
131 Id; See also MILLER & KIMMEL, supra note 119, at 302. 
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media attention.132 This creates an increased awareness among 
people as to the potential effects of exposure of personal 
information to others. Widespread reports concerning the 
dissemination and abuse of confidential information have led 
many to blame the Internet and other technologies for an overall 
diminution of privacy interests.133 The insecurity inherent in 
surrendering personal details such as social security numbers, 
addresses, and medical information, might carry over to genetic 
information as well.134 In reality, as a result of the illiteracy and 
the misconceptions described above, individuals may be more 
fearful about loss of genetic privacy than any other closely held 
privacy interests. 
In addition, the popular media repeatedly contains, with little 
basis, warnings about genetic discrimination.135 This feeds into 
the public’s general fears about invasions of privacy. Some have 
attributed public misconceptions about genetic testing to mass 
media reports which are often “misleading[,] and may confuse 
more than clarify.”136 Much of the information about genetic 
testing is learned outside the health care or research setting, 
including the learning done by health care professionals, 
insurers, and individual patients.137 
                                                          
132 See, e.g., JOHNNY R. MAY, JOHNNY MAY’S GUIDE TO PREVENTING 
IDENTITY THEFT 1-2 (2004). 
133 See, e.g., Alison Gardy, A Lost Baby, and the Pain of Endless 
Reminders in the Mail, N.Y. TIMES Sep. 20, 2005, at F5 (describing a case 
of harassment by baby product companies following woman’s failed 
pregnancy). 
134 See LAURIE, supra note 32, at 108. 
135 Hall & Rich, supra note 85, at 247; see also Neil A. Holtzman, 
Barbara A. Bernhardt, Eliza Mountcastle-Shah, Joann E. Rodgers, Ellen 
Tambor, & Gail Geller, The Quality of Media Reports on Discoveries Related 
to Human Genetic Diseases, 8 COMMUNITY GENETICS 133, 133-40 (2005) 
(Americans learn about genetic discoveries from television reports, which are 
often incomplete). 
136 Rose et al., supra note 19, at 149. 
137 See id. 
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B. Individual State Laws Are Insufficient 
There are currently thirty-three states with statutes 
specifically targeting genetic discrimination in employment. 
Additionally, every state except Mississippi, North Dakota, and 
Pennsylvania has statutes aimed at preventing genetic 
discrimination in health insurance.138 However, the individual 
provisions in these statutes offer widely varying degrees of 
protection.139 In particular, the threshold determination of what 
constitutes genetic information differs from state to state. While 
some states protect genetic information derived from individual 
or family medical histories as well as the results of genetic tests, 
others limit the protection to genetic test results alone.140 
Although state protection may seem sufficient on the surface, 
the portability of information, mobility of employees, and the 
existence of multi-state employers make individual state laws 
inadequate to address current needs.141 Due to variations in the 
protections offered by each state, multi-state employers face the 
burden of complying with a multitude of different state rules and 
regulations.142 Employees may face uncertainty when applying 
for jobs with such employers, or when considering a job 
opportunity in another state. An individual might also choose to 
forego genetic tests even if the individual lives and works in a 
state with a broad genetic discrimination statute because of the 
possibility that he may eventually move to another state in which 
his genetic information receives less protection. In order to 
effectively address the fears that are preventing people from 
pursuing genetic tests, as this note argues, uniform federal 
regulation is required. 
Despite varying degrees of state protection, a large number 
                                                          
138 National Conference of State Legislatures, Genetics Laws and 
Legislative Activity (2006), http://www.ncsl.org/programs/health/ genetics/ 
charts.htm. 
139 Id. 
140 See id. 
141 Hall & Rich, supra note 85, at 253; See also Chorpening, supra note 
20, at 1466. 
142 See Silvestri, supra note 45, at 421. 
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of people remain unprotected under state laws because the 
federal Employee Retirement Income Security Act (ERISA) 
preempts state laws, thus preventing the protection of people in 
self-funded employer plans.143 In short, state laws targeting 
genetic discrimination in health insurance only affect insurance 
plans outside of this major category. This exception to state 
protections may help explain why comparative reports on patient 
decisions to decline testing in states with or without genetic 
discrimination laws do not follow a pattern correlating to the 
existence of such laws.144 This discrepancy apparent from the 
reports indicates that state initiatives have had little overall effect 
in combating patient fears. 
 
C. Existing Federal Measures Are Insufficient 
Contrary to what GINA opponents have suggested, existing 
pre-GINA federal legislation falls short of addressing all 
concerns at stake in genetic discrimination.145 Examination of 
existing laws which might possibly address genetic 
discrimination indicates that these laws are not broad enough to 
cover all aspects of genetic discrimination and that they fail to 
allay the fears currently preventing individuals from undergoing 
genetic testing.146 The existing federal provisions include The 
Americans with Disabilities Act, Title VII of the Civil Rights 
Act, The Health Insurance Portability and Accountability Act, 
and Executive Order 13,145.147 
                                                          
143 Employee Retirement Income Security Act of 1974, Pub. L. No. 93-
406, 88 Stat. 829 (1974); See Hall & Rich, supra note 85, at 253. Nearly 
two-thirds of employers in the United States are self-insured. See Sherwin 
Chen, Negotiating a Policy of Prudent Science and Proactive Law in the 
Brave New World of Genetic Information, 53 HASTINGS L. J. 243, 259 
(2001). 
144 Hall & Rich, supra note 85, at 253. 
145 Silvers & Stein, supra note 22, at 377-78. 
146 See Katharine A. Hathaway, Federal Genetic Nondiscrimination 
Legislation: The New “Right” and the Race to Protect DNA at the Local, 
State, and Federal Level, 52 CATH. U.L. REV. 133, 138-39 (2002). 
147 42 U.S.C. § 12112 (2006) (Americans with Disabilities Act); 42 
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1. The Americans with Disabilities Act 
The Americans with Disabilities Act (ADA) prohibits certain 
employers from requesting medical information from potential 
employees prior to extending an offer of employment.148 Once 
an offer is extended, the employer may request that the potential 
employee submit to a medical examination or that he provide 
further information.149 Such requests must be uniformly made of 
all job applicants.150 Further, the exams or inquiries must be 
job-related and consistent with business necessity.151 Once these 
conditions are met, the employer may refuse to hire a disabled 
employee if reasonable accommodations cannot be made, or if 
the presence of the disability is a “direct threat” to others.152 
In order for an employee to receive protection from 
discrimination under the ADA, the employee must have a 
disability as defined by the Act.153 It is unlikely that a genetic 
defect, particularly for an individual who has the defect but is 
currently asymptomatic, qualifies as a covered disability.154 
                                                          
U.S.C. § 2000e-2(a) (2005) (Title VII of the Civil Rights Act); 29 U.S.C. § 
1182(a)(F) (2005) (Health Insurance Portability and Accountability Act); 
Exec. Order No. 13,145, 65 Fed. Reg. 6877 (2000). 
148 42 U.S.C. § 12112(d)(2)(A) (2006). The Act applies only to 
employers with fifteen or more employees. An employer with less than that 
amount is not covered. Id. at (5)(A). 
149 Id. at (d)(3). 
150 Id. at (d)(3)(A). 
151 Id. at (d)(4)(A). 
152 42 U.S.C. § 12113(b) (2006). The Act defines “direct threat” as a 
significant risk to the health or safety of others that cannot be eliminated by 
reasonable accommodation. 42 U.S.C. § 12111 (3) (2006). 
153 42 U.S.C. § 12112(a) (2006). The ADA defines “disability” as, “(A) 
a physical or mental impairment that substantially limits one or more of the 
major life activities of such individual; (B) a record of such an impairment; 
or (C) being regarded as having such an impairment.” 42 U.S.C. § 12102(2) 
(2006). It is unlikely that a genetic predisposition constitutes such a disability. 
See Holt, supra note 38, at 469-71. 
154 Holt, supra note 38, at 469-71 (discussing impairments that 
substantially limit major life activities, and judicial interpretations of 
“disability” under the ADA). 
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Additionally, individuals who are found to be carriers of a 
recessive gene would not receive protection under the Act.155 
The EEOC declared in a statement that discrimination based on 
genetic testing is covered under the ADA’s third definition of 
disability (“being regarded as” having an impairment).156 While 
courts may choose to view the EEOC statement as persuasive 
when faced with an individual genetic discrimination claim, they 
are by no means bound by it.157 Indeed, as demonstrated by 
Sutton v. United Airlines, in which the Supreme Court clearly 
rejected an EEOC statement regarding another ADA provision, 
the EEOC’s interpretation is not always dispositive.158 In 
addition, under the “regarded as” definition of disability, courts 
have held that the employer must actually be mistaken as to the 
disability’s existence.159 Often, an employer may refuse a job 
applicant employment in order to avoid the risk that the potential 
                                                          
155 A recessive gene is one that can only be expressed when the 
individual has inherited a copy of the recessive gene from both of the 
individual’s parents. In a carrier of a recessive gene, only one copy of the 
gene is present, and therefore the gene will not be expressed. Such an 
individual is not only presently asymptomatic, but also does not sustain any 
predisposition for future disability caused by the gene. See Schoonmaker & 
Williams, supra note 91, at 4 and n.18. Yet under current federal laws, this 
person does not receive any assurances of protection from discrimination. See 
Pagnattaro, supra note 110, at 165. 
156 EEOC Compliance Manual, Definition of the Term Disability, 
§ 902.8(a) (1995). 
157 Holt, supra note 38, at 465. 
158 Sutton v. United Air Lines, 527 U.S. 471, 482 (1999). The Supreme 
Court disagreed with the EEOC interpretation of disability to include 
correctable disabilities such as vision impairment. Id. 
159 EEOC v. Rockwell Int’l Corp., 60 F. Supp. 2d 791 (N.D. Ill. 1999), 
aff’d, 243 F.3d 1012 (7th Cir. 2001) (holding that an employer may reject 
applicants who have a propensity to future disability, as long as the employer 
is not regarding the applicants as currently disabled); Sutton v. United Air 
Lines, 527 U.S. 471, 484-85 (1999) (holding that rejection of applicants 
seeking positions as airline pilots because they required corrective lenses for 
vision impairments was not barred by the ADA. The employer knew that the 
applicants’ vision with corrective lenses in place was not impaired, thus it did 
not regard the applicants as currently disabled). 
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employee may develop an impairment in the future.160 Thus the 
employer has not regarded the applicant as having any current 
impairment.161 Accordingly, an individual with a genetic 
predisposition to illness who is as yet asymptomatic, may be 
barred from bringing suit under the ADA if the employer 
refuses to hire the individual in order to avoid a future risk.162 
The statutory language of the ADA has contributed to a 
relatively narrow interpretation of “disability,” as it cites the 
Congressional finding that there are around 43 million 
Americans with disabilities.163 An expansion of ADA protected 
disabilities to include genetic defects would implicate virtually 
every living person,164 undermining the legislative intent to 
provide specific protection to the 43 million people currently 
classified as disabled.165 Such an inclusion would serve as a 
validation of common misperceptions about genetic 
information.166 It would lead to the incorrect assumption that 
genetic predisposition to disease is in fact an impairment.167 
Clearly, this would discourage people from undergoing testing. 
Although the Supreme Court has not directly addressed the 
issue, the Court has hinted that it will not allow the inclusion of 
genetic predispositions in the ADA’s definition of disability.168 
                                                          
160 See Chorpening, supra note 20, at 1453-54; Silvers & Stein, supra 
note 22, at 379. 
161 Chorpening, supra note 20, at 1454; see also EEOC v. Rockwell, 60 
F. Supp. 2d 791 (N.D. Ill. 1999), aff’d, 243 F.3d 1012 (7th Cir. 2001). 
162 See Chorpening, supra note 20, at 1454. 
163 42 U.S.C. § 12101(a)(1) (2006). 
164 Hearings on Genetic Information in the Workplace: Hearing Before 
the Senate Comm. on Health, Educ., Labor and Pensions, 106th Cong. 
(2000) (testimony of Francis S. Collins, M.D., Ph.D., Director of National 
Human Genome Research Institute), available at 
http://www.genome.gov/10001380. 
165 Chorpening, supra note 20, at 1458. 
166 See discussion of common misperceptions supra, Part IV.A(2). 
167 Holt, supra note 38, at 482. 
168 See Bragdon v. Abbot, 524 U.S. 624, 661 (1998) (Rehnquist, C.J., 
concurring in part and dissenting in part) (comparing an individual with 
presymptomatic HIV to an individual with a genetic marker for a debilitating 
disease, in that neither impairment substantially limits a major life activity, as 
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For example, in Chevron U.S.A., Inc. v. Echazabal, the 
Supreme Court allowed an extension of the “direct threat to 
others” defense to cover threats to oneself as well as to 
others.169 The Court upheld the denial of employment to an 
individual with a medical condition that might become worse in 
the particular work environment.170 Under this expanded 
definition of “direct threat,” employers are given a broader 
defense to ADA claims that could allow genetic factors to be 
considered in hiring decisions.171 
Other judicial opinions have demonstrated that the scope of 
the ADA does not extend to genetic discrimination. In EEOC v. 
Rockwell, a Seventh Circuit case, an employer used predictive 
medical tests to screen potential employees for an indicator that 
they may develop a particular disability in the future.172 The 
applicants were not disabled at the time of the test, nor was 
there any guarantee that they would become disabled in the 
                                                          
required for inclusion in the ADA); Sutton v. United Air Lines, 527 U.S. 
471, 487 (1999) (holding that correctable myopia may not be considered a 
disability under the ADA because such inclusion would encompass too many 
people). Both of these opinions cautioned against an over-inclusive definition 
of disability under the ADA which could then extend the scope far beyond 
the intention of Congress. 
169 Chevron U.S.A. Inc. v. Echazabal, 536 U.S. 73, 78-79 (2002). 
170 Id. The case involved an individual who was denied employment at 
an oil refinery when a post-offer physical exam revealed that he had a liver 
condition which could be exacerbated over time. Id. In a post-Echazabal 8th 
Circuit case, an insulin-dependent diabetic was denied employment at a 
single-pharmacist pharmacy which did not provide for uninterrupted meal 
breaks. The court noted that the employer could validly assert a “direct threat 
to self” argument. Orr v. Wal-Mart Stores, Inc. 297 F.3d 720 (8th Cir. 
2002). 
171 See, e.g., Silvers & Stein, supra note 22, at 380. GINA does not 
contain a “direct threat” defense, thus broadening the scope of the prohibited 
discrimination. See H.R. 1227, 109th Cong. (2005). 
172 EEOC v. Rockwell, 60 F. Supp. 2d 791 (N.D. Ill. 1999), aff’d, 243 
F.3d 1012 (7th Cir. 2001). Job applicants at the Rockwell International 
Corporation were required to undergo nerve conduction tests to detect the 
presence of neuropathy, a condition which indicates susceptibility of an 
individual to the development of nerve disorders such as carpal tunnel 
syndrome. Id. at 1014. 
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future.173 Yet the employer rejected applicants who had a 
propensity to develop the disability.174 The court found that the 
employer did not violate the ADA because the individuals were 
not currently disabled, and the employer did not mistakenly 
regard them as disabled.175 This decision points toward the 
conclusion that genetic discrimination by employers will not be 
barred by the ADA, as most employers use genetic information 
in a predictive manner, rather than as an indicator of a current 
disability.176 
2. Title VII of the Civil Rights Act 
Title VII of the Civil Rights Act is also an inadequate means 
of addressing genetic discrimination because while it prohibits an 
employer from basing an employment decision on race, color, 
religion, sex, or national origin,177 genetic discrimination does 
not readily fit into any of these categories. Although a small 
percentage of genetic diseases closely correlate with race, sex, 
or national origin, no disease is exclusively linked to these 
factors.178 
Title VII yields a cause of action for genetic discrimination 
only to the extent that an employer chooses to single out job 
applicants belonging to a particular Title VII category for a 
genetic test. For example, in Norman-Bloodsaw v. Lawrence 
Berkeley Laboratory, an employer subjected its black and female 
employees to genetic testing for sickle cell trait, syphilis, and 
pregnancy.179 The court found that the employees’ claims under 
Title VII were valid, as the discriminatory acts of the employer 
specifically targeted members of the Title VII categories of race 
                                                          
173 Id. 
174 Id. 
175 Id. at 1018. 
176 See Holt, supra note 38, at 468. 
177 42 U.S.C. § 2000e-2(a) (2005). 
178 Chorpening, supra note 20, at 1463. 
179 Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1265 
(9th Cir. 1998). 
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and sex.180 Although the genetic discrimination in Norman-
Bloodsaw violated Title VII, much of the fear about genetic 
discrimination arises in situations in which employers 
discriminate purely on the basis of a genetic factor that 
predisposes an individual to illness. Such discrimination does not 
correlate to any category of individuals protected under the 
existing Title VII. 181 
This discrepancy has led some to suggest modification of 
Title VII’s categories to include genetic predispositions.182 
However, doing so would prevent employers from considering 
the potential impact of the genetic predisposition on workplace 
safety, including threats to other employees or the general 
public.183 Genetic information is unlike race, sex, religion, and 
national origin in that it at times raises valid concerns over 
public safety and welfare.184 Yet under Title VII, exceptions 
such as threat to others or business necessity are not 
permitted.185 
3. The Health Insurance Portability and Accountability Act 
The earliest Congressional attempt to specifically address 
genetic discrimination was included in the Health Insurance 
Portability and Accountability Act (HIPAA) of 1996.186 
Although the legislation contains a specific provision prohibiting 
health insurers from denying coverage based on genetic data 
about an individual, it does not prevent the insurer from 
                                                          
180 Id. at 1271-72. 
181 Chorpening, supra note 20, at 1463. 
182 Holt, supra note 38, at 481-82. 
183 Chorpening, supra note 20, at 1464. 
184 Id. For example, an airplane pilot with a genetic predisposition that is 
highly predictive of a propensity for epileptic seizures at high altitudes may 
be a valid safety concern for the airline; But see Holt, supra note 38, at 482 
(arguing that a Title VII modification is appropriate because genetic 
discrimination is another form of “inappropriate prejudices”). 
185 See Chorpening, supra note 20, at 1464. 
186 Health Insurance Portability and Accountability Act, 29 U.S.C. § 
1182(a)(F) (2005). 
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increasing premiums for groups based on genetic data. 187 The 
provisions of HIPAA apply only to group health insurers, and 
not to privately held plans.188 Further, the statute does not define 
“genetic information,” leaving open the possibility that 
information obtained from family medical histories may not be 
protected.189 Genetic discrimination in workplace employment 
decisions is not addressed by HIPAA.190 The narrow focus of 
this legislation does little to persuade people to undergo genetic 
testing.191 
4. Executive Order 13,145 
In an acknowledgment of the need for regulation of the use 
of genetic information by employers, President Clinton issued 
Executive Order 13,145 in February 2000.192 While this Order 
addresses some of the concerns about genetic discrimination, it 
applies only in the context of federal employers.193 The Order 
can do little to alleviate concerns about discrimination, as it does 
not address insurers, and it has no effect on non-federal 
employers.194 In addition, the Order provides an exception for 
employers who use genetic information “exclusively to assess 
whether further medical evaluation is needed to diagnose a 
current disease, condition, or disorder.”195 Because the Order 
contains no further elucidation of the terms “disease, condition, 
or disorder,” employers may be able to retain significant 
                                                          
187 29 U.S.C. § 1182(b)(2) (2005). 
188 Id. at (a)(1) (2005). 
189 See Dolgin, supra note 36, at 783. 
190 Chorpening, supra note 20, at 1467. 
191 Hall & Rich, supra note 85, at 249; See also Green & Thomas, supra 
note 54, at 571 (finding that HIPAA is not a sufficient means of addressing 
genetic discrimination). 
192 Exec. Order No. 13,145, 65 Fed. Reg. 6877 (2000). 
193 Id. The Order includes provisions barring federal employers from 
using protected genetic information in hiring, firing, and employee 
compensation decisions. Id. 
194 Id. 
195 Id. 
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flexibility in their use of genetic information.196 
D. Other (Non-Legislative) Methods of Circumventing the 
Fears are Inadequate 
Because it is the fear of genetic discrimination, rather than 
genetic discrimination itself, that is at the root of this problem, 
the use of legislation to combat it must be carefully weighed. 
Policy makers need to be aware of the complexities of 
influencing a behavioral change in people, and the law should 
not be treated “as a simple ‘tool’ for influencing . . . complex 
behaviors.”197 Legislating on the basis of existing fears, rather 
than existing unwanted activity, presents unique challenges such 
as an increased opportunity for unintended consequences and an 
increased possibility of unnecessary regulation.198 In addition, it 
has been suggested that rather than using legislation to eliminate 
all of the risk, educational initiatives should be undertaken with 
a focus on “increasing more accurate perception of the risk.”199 
Increased public education about the nature of genetic 
information could effectively alleviate fears and 
misconceptions.200 Arguably, implementation of educational 
                                                          
196 See Jennifer Krumm, Why Congress Must Ban Genetic Discrimination 
in the Workplace, 23 J. LEGAL MED. 491, 516 (2002). “[M]any different 
personality traits and characteristics could fit within these exceptions.” Id. 
197 Scott Burris, Driving the Epidemic Underground: A New Look at Law 
and the Social Risk of HIV Testing, 12 AIDS & PUBLIC POLICY J. 66, 72 
(1997). 
198 Letter from Genetic Information Nondiscrimination in Employment 
Coalition, U.S. Chamber of Commerce, Re: S.1053, the Genetic Information 





199 Hall & Rich, supra note 85, at 255. 
200 Id. at 254-55. This is also the view of The U.S. Chamber of 
Commerce, a major opponent of GINA. See Genetic Non-Discrimination: 
Examining the Implications for Workers and Employers: Hearing Before the 
H. Subcomm. on Employer-Employee Relations of the H. Comm. on 
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initiatives such as government-sponsored public courses on basic 
genetics and improvement of cross-disciplinary communication 
between scientists, policy makers, and ethicists, can succeed in 
raising public awareness to some extent.201 Furthermore, some 
commentators predict that in the future, genetic information will 
become such a fundamental part of our lives that people will 
inevitably learn how to understand and interpret the information 
in an appropriate way.202 
However, the current state of scientific understanding in the 
general population is extremely low.203 Genetic science has 
quickly become a major medical and scientific force, requiring 
that policy decisions be made rapidly, leaving little time to carry 
out major educational campaigns.204 The most practical solution 
to address the current needs of patients may be legislation, or at 
the very least, a combination of legislative and educational 
initiatives, because the time required to effect a change of public 
sentiment is daunting.205 The mere possibility that public 
understanding of genetic science will improve in the future does 
not preclude the necessity for immediate action to address the 
current state of affairs. Further, GINA provides for the 
establishment of a committee to evaluate the status of the 
implemented legislation after a period of time, at which point 
any change in public acceptance of or attitudes toward genetic 
testing can be accounted for.206 
                                                          
Education and the Workforce, 108th Congress (2004) (statement of Lawrence 
Z. Lorber, Partner, Proskauer Rose, LLP, on behalf of the U.S. Chamber of 
Commerce). 
201 See Chen, supra note 143, at 257. 
202 John C. Fletcher and Dorothy Wertz, Ethics, Law, and Medical 
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19, at 150. 
206 H.R. 1227, § 208(b) (2005). 
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E. The Significance of Genetic Testing for Public Healthcare 
and Scientific Research 
Because of the significance of genetic testing in two 
spheres—that of the advancement of scientific research,207 and 
that of the individual’s pursuit of optimal healthcare208—efforts 
must be made to address public fears and promote wider public 
acceptance of these tests. Indeed, the unique importance of the 
tests may be considered yet another distinguishing factor 
between genetic discrimination and discrimination based on other 
health-related information.209 The unique challenges of using 
legislation to target an existing fear are balanced by the unique 
importance of genetic testing.210 Whether or not the fear of 
genetic discrimination is justified, the fact remains that it is 
preventing people from receiving the wide range of benefits of 
recent scientific progress.211 This concern speaks to the urgency 
of the need for comprehensive federal legislation.212 
The individual who undergoes genetic testing may glean 
important information leading to better prevention and treatment 
options. For example, individuals with genetic mutations that 
indicate a high susceptibility to colorectal cancer can follow 
recommended guidelines such as undergoing a routine 
colonoscopy beginning at age 25.213 A woman who learns that 
she is at a high risk for developing breast cancer due to 
mutations in her BRCA1 or BRCA2 genes may increase her 
screenings or take other preventative measures.214 Other 
                                                          
207 Rose et al., supra note 19, at 145. 
208 See R. Verhoeff, Physicians’ Perception of Genomic Medicine, 8 
COMMUNITY GENETICS 184, 184 (2005). 
209 See Hellman, supra note 37, at 93. 
210 The challenges are described supra, Part IV.D. 
211 See, e.g., Silvers & Stein, supra note 22, at 377. 
212 See Gina Kolata, Using Gene Tests to Customize Medical Treatment, 
N.Y. TIMES, Dec. 20, 1999, at A1 (quoting Dr. Francis Collins, director of 
The National Human Genome Research Institute). 
213 Rose et al., supra note 19, at 145. 
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RIVKA 3/4/2007 12:41 AM 
 PUBLIC FEARS ABOUT GENETIC TESTING 245 
important applications of genetic test results for healthcare 
include characterization of leukemias in order to tailor treatment 
options accordingly, and new tests available to determine the 
efficiency of specific drugs when used in conjunction with 
specific genetic profiles.215 
In situations in which the need for genetic testing is crucial, 
it is unlikely that fear of genetic discrimination will prevent 
people from pursuing it.216 Those who are already exhibiting 
signs of a disease are not likely to be deterred from undergoing 
a test to confirm a diagnosis.217 In that instance, their 
insurability will not significantly change because the carrier will, 
at any rate, establish that he has the disease from clinical 
reports.218 Additionally, most prenatal genetic testing is not 
affected by patient fears of genetic discrimination.219 This is 
attributable to the nature of such tests, as they target 
spontaneous mutations (which have no implication for other 
family members), and a result indicating a severe genetic 
abnormality usually leads to termination of the pregnancy.220 
In other situations, the deterrent fears may not have any 
serious implications for patients. For example, for those who 
have a significant family history of a disease, testing is often not 
critical because those individuals are already aware that they are 
at a high risk and are likely taking preventative measures. For 
this group, test results indicating a high propensity for the 
disease will change nothing, and the patient, anticipating future 
illness, will likely conclude that the test is not worth the risk of 
losing their insurance.221 Additionally, some available genetic 
                                                          
years or bilateral mastectomy. Id. 
215 At least two new drug treatments, Herceptin for breast cancer and 
Azathioprine for inflammatory bowel disease, are designed for use only in 
populations with a particular genetic factor. See Schoonmaker & Williams, 
supra note 92, at n.29. 
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tests are thought to be entirely unnecessary.222 These include 
tests for diseases that cannot be prevented, and for which 
knowledge of one’s genetic risk will not have any practical 
significance.223 
The opportunities yielded by the Human Genome Project for 
the improvement of public health will remain limited by 
scientific investigation into the impact of particular genetic 
sequences on human conditions. Accordingly, the National 
Human Genome Research Institute has created the Genomes to 
Life initiative, which is committed to scientific research into the 
clinical significance of the data acquired by the Human Genome 
Project.224 However, in order to accomplish this, scientists 
depend on the willingness of individuals to undergo genetic 
testing for research purposes. This willingness has been 
compromised by fears of resultant discrimination in employment 
or health insurance.225 
Comprehensive federal legislation must be in place in order 
to allay the concerns of people contemplating undergoing 
testing, whether for purposes of scientific research studies or 
personal health, because of the critical importance of genetic 
testing in these two spheres.226 A common law evolutionary 
model, which allows the common law to evolve over time to 
deal with developments not contemplated by existing laws,227 
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will not suffice in this case. While it is possible that existing 
laws might ultimately grow to address some of the concerns 
about genetic discrimination, time constraints make this option 
unworkable. The passage of time will significantly delay much 
needed scientific progress as well as serve to deprive patients of 
critical information that could be obtained from genetic testing. 
CONCLUSION 
The Genetic Information Nondiscrimination Act, as 
described above, currently awaits attention in the House of 
Representatives.228 Genetic nondiscrimination legislation is 
sorely needed, as existing measures do not sufficiently address 
the complexities of genetic discrimination. Although the 
necessity for legislation has most likely been fueled by general 
misunderstanding and/or ignorance of the underlying scientific 
bases for genetic testing, the current state of affairs results in 
vulnerable populations failing to benefit from potentially life-
saving or life-altering medical advances. Therefore, in the 
absence of non-legislative solutions, Congressional legislative 
power, as this note argues, must address the issue. 
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